Immunosuppression in Organ Transplantation.
نویسندگان
چکیده
منابع مشابه
Immunosuppression in organ transplantation.
The immunological barrier remains the major obstacle to the widespread use of transplantation as a replacement therapy for terminal organ failure. Since the first successful renal transplant, performed by Hume et al. (1952), there has been an elusive search for agents that can render the immune mechanism unresponsive to the specific alloantigen stimulus of the engrafted organ, while sparing non...
متن کاملCurrent Immunosuppression in Abdominal Organ Transplantation
Organ transplantation has saved the lives of thousands of patients beginning from the mid 1950s. At the end of 2007 the Organ Procurement and Transplantation Network (OPTN) database recorded 183,222 people living with a functioning graft in the United States (Wolfe et al., 2010). Over the last two decades survival rates have continued to improve and currently 81-91% of kidney transplant recipie...
متن کاملTolerance in Organ Transplantation: From Conventional Immunosuppression to Extracellular Vesicles
Organ transplantation is often the unique solution for organ failure. However, rejection is still an unsolved problem. Although acute rejection is well controlled, the chronic use of immunosuppressive drugs for allograft acceptance causes numerous side effects in the recipient and do not prevent chronic allograft dysfunction. Different alternative therapies have been proposed to replace the cla...
متن کاملRole of Immunosuppression Minimization Protocols in Renal Transplantation
The subject of transplant immunosuppression has generated significant interest in recent years. Excellent immunosuppression, advances in surgical technique, post-transplantation care, and infection control have resulted in excellent outcomes. There is widespread support for the notion that the fundamental objective in transplant immunology should be the achievement of specific graft toleran...
متن کاملImmunosuppression in lung transplantation.
Lung transplantation can be a life-saving procedure for those with end-stage lung diseases. Unfortunately, long term graft and patient survival are limited by both acute and chronic allograft rejection, with a median survival of just over 6 years. Immunosuppressive regimens are employed to reduce the rate of rejection, and while protocols vary from center to center, conventional maintenance the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacology
سال: 1994
ISSN: 0021-5198
DOI: 10.1016/s0021-5198(19)35809-3